¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"sticky end"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • end-systolic volume
    ¼öÃà±â¸»¿ëÀû(¡­éÄîÝ)
  • end-tidal air
    È£Èí(û¼ýå) Á¾¸»È£±â(ðûØÇû¼Ñ¨).
  • end-to-side anastomosis
    ´ÜÃø¹®ÇÕ¼ú.
  • free end saddle partial denture
    À¯¸®´Ü±¹ºÎÀÇÄ¡.
  • hair on end pattern
    °ïµÎ¼± ¸ð¹ß ÇüÅÂ
  • left ventricular end-diastolic pressure
    Á½ɽÇÀ̿ϱ⸻¾Ð
  • left ventricular end-diastolic volume
    Á½ɽÇÀ̿ϱ⸻¿ëÀû
  • left ventricular end-diastolic volume
    Á½ɽÇÈ®À帻±â¿ëÀû(¡­üªíåØÇÑ¢é»îÝ).
  • lower end of sacral canal
    õ°ñ¿­°ø.
  • lower end of sacral canal ³ª hiatus sacralis
    õ°ñ¿­°ø.
  • miniature end plate potential =MEPP
    ½Å°æ,»ý¸®,¾à¸®²¿¸¶Á¾ÆÇÀü¾Ð(ðû÷ùï³äâ)
  • miniature end plate potential =MEPP
    ¹Ì¼¼Á¾ÆÇÀüÀ§(Ú°á¬ðû÷ùï³êÈ).
  • miniature end plate potential =MEPP
    [½Å°æ,»ý¸®,¾à¸®]¹Ì¼¼Á¾ÆÇÀüÀ§(Ú°á¬ðû÷ùï³êÈ).
  • motor end plate
    ¿îµ¿Á¾ÆÇ(¡­ðû÷ù).
  • mucocutaneous end-organ
    Á¡¸· ÇǺΠ¸»´Ü±â°ü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
EDV End Diastolic Volume
ESRD End Stage Renal Disease
LVEDV Left Ventricular End-Diastolic Volume
LVESV Left Ventricular End-Systolic Volume
NEEP Negative End-Expiratory Pressure
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ESRF End Stage Renal Failure
EES End Systolic Elastance
ESV End Systolic volume
ED End diastole
EDV End diastolic
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
end-diastolic volume The amount of blood in the ventricle immediately before a cardiac contraction begins; a measurement of cardiac filling between beats, related to diastolic function.
(05 Mar 2000)
end-feet The somewhat enlarged, often club-shaped endings by which axons make synaptic contacts with other nerve cells or with effector cells (muscle or gland cells). As isolated, by homogenizing brain or spinal cord, they contain acetylcholine and the related enzymes. Terminals contain neurotransmitters of various kinds, sometimes more than one. These can be demonstrated by chemical analysis and immunocytochemical methods.
See: synapse.
Synonym: axonal terminal boutons, end-feet, neuropodia, pieds terminaux, synaptic boutons, synaptic endings, synaptic terminals, terminal boutons, bouton terminaux.
(05 Mar 2000)
end-filling The use of DNA polymerase to create a blunt end (both strands are the same length and end together) on double-stranded DNA that has a staggered end (one strand is longer than the other so there is a single-stranded section at the end of the molecule).
(09 Oct 1997)
end-on mattress suture A vertical mattress suture used for exact skin approximation.
(05 Mar 2000)
end organ The special structure containing the terminal of a nerve fibre in peripheral tissue such as muscle, tissue, skin, mucous membrane, or glands.
See: ending.
(05 Mar 2000)
end oxidation <biochemistry> The last oxidation step in a catabolic pathway.
Synonym: terminal oxidation.
(05 Mar 2000)
end-piece The terminal part of the tail of a spermatozoon consisting of the axoneme and the flagellar membrane.
(05 Mar 2000)
end plate <anatomy, physiology> The area of sarcolemma immediately below the synaptic region of the motor neuron in a neuromuscular junction. most often refers to the end of a nerve fibre against a skeletal muscle fibre, to which it transmits nerve signals.
(18 Nov 1997)
end plate potential <physiology> Depolarisation of the sarcolemma as a result of acetylcholine release from the motoneuron causing an influx of sodium ions. The endplate potential is the sum of quantal miniature endplate potentials. Development of the end plate potential is blocked by curare.
(18 Nov 1997)
end point <chemistry> It is the completion point during a titration reaction where there are equal amounts of titrant and whatever is being titrated. It is usually evident by the first perceptible alteration of the colour of an added indicator.
<immunology> It is the most dilute an antibody or antiserum solution can be while still detectably reacting with the antigen.
<statistics> A category of data used to compare the outcome in different arms of a clinical trial. Common endpoints are severe toxicity, disease progression or fall in such surrogate markers as CD4 count, but sometimes death is used as an endpoint.
(08 Mar 2000)
end-point measurement Analytical measurement at the end of a chemical reaction, as opposed to making the measurement while the reaction proceeds.
(05 Mar 2000)
end-point nystagmus A jerky, physiologic nystagmus occurring in a normal individual when attempts are made to fixate a point at the limits of the field of fixation.
Synonym: deviational nystagmus.
(05 Mar 2000)
end product <biochemistry> The final product of after a series of reactions with enzymes in a biochemical metabolic pathway has taken place.
(09 Oct 1997)
end product inhibition <biochemistry, physiology> The process of the end product of a particular metabolic reaction inhibiting an allosteric enzyme involved in that reaction as the reaction starts again, thus breaking the reaction cycle.
(09 Oct 1997)
end product repression Catabolite repression in which the catabolite is an end product of a particular pathway.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • end use
    ÃÖÁ¾ ¿ëµµ
  • end user
    ÃÖÁ¾ ¼ö¿äÀÚ;½Ç¼ö¿äÀÚ
  • end ways
    ³¡À» À§·ÎÇϰí;¼¼·Î
  • end zone
    ¿£µå Á¸(°ñ¶óÀΰú ¿£µå¶óÀÎ »çÀÌÀÇ ±¸¿ª)
  • end-
    (¿¬°áÇü)(³»ºÎ,Èí¼ö)ÀÇ ¶æ
  • fag end
    µµ·Á³½ ³¡ Á¶°¢;¸»´Ü;³²Àº Çã¼·¾²·¹±â;´ã¹è;Åä²ø;»õ³¢ÀÇ ²¿Áö ¾ÊÀº ²ôÆ®·¯¹Ì
  • front end
    ÇÁ·ÐÆ® ¿£µå(ÁõÆø,Áß°£ Á֯ļö º¯È¯ºÎ)
  • gable end
    ¹Ú°øº®
  • head end
    (À¯¼± ÅÚ·¹ºñÁ¯ÀÇ)ÀüÆÄ Áß°è¼Ò
  • hind end
    ¾ûµ¢ÀÌ
  • rear end
    ÈĺÎ;ÈĹÌ;±ÃµÕÀÌ
  • rear-end
    ÈĺÎÀÇ;ÈĹÌÀÇ
  • receiving end
    ¹Þ´Â ÂÊ;½È¾îµµ ¹Þ¾ÆµéÀÏ ¼ö ¹Û¿¡ ¾ø´Â »ç¶÷;Èñ»ýÀÚ;Æ÷¼öÀÇ ¼öºñ À§Ä¡
  • repe's end
    ¹åÁ٠äÂï;±³¼ö¿ë ¹åÁÙ
  • tag end
    ¸¶Áö¸· ºÎºÐ(´ë¸ñ);³¡Å丷;ÀÚÅõ¸®;Á¾¸»;¸»±â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á